SG11201610600SA - Methods of cancer treatment with antagonists against pd-1 and pd-l1 in combination with radiation therapy - Google Patents

Methods of cancer treatment with antagonists against pd-1 and pd-l1 in combination with radiation therapy

Info

Publication number: SG11201610600SA
Authority: SG; Singapore
Prior art keywords: methods; combination; radiation therapy; cancer treatment; antagonists against
Prior art date: 2014-06-17

Application number

SG11201610600SA

Inventor

Ross Stewart

Michelle Morrow

Robert Wilkinson

Edmund Poon

Simon Dovedi

Tim Illidge

Original Assignee

Medimmune Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-06-17

Filing date

2015-06-17

Publication date

2017-01-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53498965&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201610600S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-06-17 Application filed by Medimmune Ltd filed Critical Medimmune Ltd

2017-01-27 Publication of SG11201610600SA publication Critical patent/SG11201610600SA/en

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Mycology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Oncology (AREA)
Pathology (AREA)
Radiology & Medical Imaging (AREA)
Hematology (AREA)
Endocrinology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Radiation-Therapy Devices (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SG11201610600SA 2014-06-17 2015-06-17 Methods of cancer treatment with antagonists against pd-1 and pd-l1 in combination with radiation therapy SG11201610600SA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201462013157P	2014-06-17	2014-06-17
PCT/EP2015/063552 WO2015193352A1 (en)	2014-06-17	2015-06-17	Methods of cancer treatment with antagonists against pd-1 and pd-l1 in combination with radiation therapy

Publications (1)

Publication Number	Publication Date
SG11201610600SA true SG11201610600SA (en)	2017-01-27

Family

ID=53498965

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG11201610600SA SG11201610600SA (en)	2014-06-17	2015-06-17	Methods of cancer treatment with antagonists against pd-1 and pd-l1 in combination with radiation therapy
SG10202108654PA SG10202108654PA (en)	2014-06-17	2015-06-17	Methods of cancer treatment with antagonists against pd-1 and pd-l1 in combination with radiation therapy

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SG10202108654PA SG10202108654PA (en)	2014-06-17	2015-06-17	Methods of cancer treatment with antagonists against pd-1 and pd-l1 in combination with radiation therapy

Country Status (19)

Country	Link
US (2)	US10092645B2 (en)
EP (2)	EP3157629B1 (en)
JP (4)	JP6877147B2 (en)
KR (3)	KR102592781B1 (en)
CN (1)	CN107073107A (en)
AU (3)	AU2015276173B2 (en)
BR (1)	BR112016028964A2 (en)
CA (1)	CA2950046C (en)
DK (1)	DK3157629T3 (en)
ES (1)	ES2933603T3 (en)
HU (1)	HUE060689T2 (en)
IL (1)	IL249133B (en)
MX (3)	MX2016015346A (en)
PL (1)	PL3157629T3 (en)
PT (1)	PT3157629T (en)
RU (1)	RU2711408C2 (en)
SG (2)	SG11201610600SA (en)
TW (2)	TWI781021B (en)
WO (1)	WO2015193352A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP6550053B2 (en)	2013-09-11	2019-07-24	メディミューンリミテッド	Anti-B7-H1 antibody for treating a tumor
PT3081576T (en)	2013-12-12	2019-10-15	Jiangsu Hengrui Medicine Co	Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
TWI680138B (en)	2014-01-23	2019-12-21	美商再生元醫藥公司	Human antibodies to pd-l1
TWI681969B (en)	2014-01-23	2020-01-11	美商再生元醫藥公司	Human antibodies to pd-1
WO2015109391A1 (en)	2014-01-24	2015-07-30	Children's Hospital Of Eastern Ontario Research Institute Inc.	Smc combination therapy for the treatment of cancer
WO2016066634A2 (en) *	2014-10-27	2016-05-06	Ruprecht-Karls-Universität Heidelberg	Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer
TWI609687B (en)	2015-04-14	2018-01-01	美國禮來大藥廠	Targeted treatment of leiomyosarcoma
WO2016196389A1 (en) *	2015-05-29	2016-12-08	Bristol-Myers Squibb Company	Treatment of renal cell carcinoma
KR20220131277A (en)	2015-09-01	2022-09-27	아게누스 인코포레이티드	Anti-pd-1 antibodies and methods of use thereof
BR112018015485A2 (en)	2016-02-06	2018-12-18	Epimab Biotherapeutics Inc	fabs-in-tandem immunoglobulin and its uses
US10980894B2 (en)	2016-03-29	2021-04-20	Obi Pharma, Inc.	Antibodies, pharmaceutical compositions and methods
CA3020918A1 (en)	2016-04-12	2017-10-19	Eli Lilly And Company	Combination therapy with notch and pi3k/mtor inhibitors for use in treating cancer
KR102418765B1 (en)	2016-04-12	2022-07-08	일라이 릴리 앤드 캄파니	Combination Therapy of Notch and CDK4/6 Inhibitors for the Treatment of Cancer
SG11201809024UA (en)	2016-04-22	2018-11-29	Obi Pharma Inc	Cancer immunotherapy by immune activation or immune modulation via globo series antigens
AR108377A1 (en) *	2016-05-06	2018-08-15	Medimmune Llc	BISPECIFIC UNION PROTEINS AND ITS USES
TWI755395B (en)	2016-05-13	2022-02-21	美商再生元醫藥公司	Combination of anti-pd-1 antibodies and radiation to treat cancer
WO2017200969A1 (en) *	2016-05-20	2017-11-23	Eli Lilly And Company	Combination therapy with notch and pd-1 or pd-l1 inhibitors
CN110072545A (en)	2016-07-27	2019-07-30	台湾浩鼎生技股份有限公司	Immunogenicity/therapeutic glycan pool object and application thereof
KR102528998B1 (en)	2016-07-29	2023-05-03	오비아이 파머 인코퍼레이티드	Human Antibodies, Pharmaceutical Compositions and Methods
CA3039405A1 (en)	2016-10-12	2018-04-19	Eli Lilly And Company	Targeted treatment of mature t-cell lymphoma
EP3532494A4 (en)	2016-10-26	2020-06-03	The Children's Medical Center Corporation	Methods and compositions for modulaton of transforming growth factor beta-regulated functions
CA3046082A1 (en)	2016-12-07	2018-06-14	Agenus Inc.	Antibodies and methods of use thereof
ES2949364T3 (en)	2017-02-17	2023-09-28	Fred Hutchinson Cancer Center	Combination Therapies for the Treatment of BCMA-Related Cancers and Autoimmune Disorders
JP7324710B2 (en)	2017-02-21	2023-08-10	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	Anti-PD-1 antibody for treatment of lung cancer
US11603407B2 (en)	2017-04-06	2023-03-14	Regeneron Pharmaceuticals, Inc.	Stable antibody formulation
WO2019094265A1 (en) *	2017-11-10	2019-05-16	Armo Biosciences, Inc.	Pd1 polypeptide binding molecules
JP7312168B2 (en) *	2017-11-13	2023-07-20	クレッシェンド、バイオロジックス、リミテッド	A single domain antibody that binds to CD137
CA3093740A1 (en)	2018-03-22	2019-09-26	Surface Oncology, Inc.	Anti-il-27 antibodies and uses thereof
US10949272B2 (en) *	2018-06-14	2021-03-16	Microsoft Technology Licensing, Llc	Inter-application context seeding
JP2022511471A (en)	2018-12-03	2022-01-31	フュージョンファーマシューティカルズインコーポレイテッド	Combination therapy of radioactive immune complex and DNA damage and repair inhibitors
KR102167539B1 (en) *	2018-12-28	2020-10-20	한국원자력의학원	Method for providing information for predicting the prognosis of radiation therapy, comprising step of measuring the expression level of immune checkpoint of cancer cell which is changed during the radiation therapy, and composition for radiation therapy
KR102195221B1 (en) *	2019-12-31	2020-12-24	서울대학교산학협력단	Pharmaceutical composition for combination of radiotherapy for treating triple negative breast cancer comprising phosphatidylinositol 3-kinase inhibitor and programmed cell death protein 1 inhibitor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MXPA05006828A (en)	2002-12-23	2005-09-08	Wyeth Corp	Antibodies against pd-1 and uses therefor.
US9132281B2 (en)	2011-06-21	2015-09-15	The Johns Hopkins University	Focused radiation for augmenting immune-based therapies against neoplasms
CN102935228B (en)	2011-08-15	2015-02-18	苏州丁孚靶点生物技术有限公司	Reagent for tumor treatment, its use and method
HUE051954T2 (en)	2011-11-28	2021-03-29	Merck Patent Gmbh	Anti-pd-l1 antibodies and uses thereof
EP2744830A4 (en)	2012-06-21	2015-06-17	Compugen Ltd	Lsr antibodies, and uses thereof for treatment of cancer
US9682143B2 (en) *	2012-08-14	2017-06-20	Ibc Pharmaceuticals, Inc.	Combination therapy for inducing immune response to disease
ES2660027T3 (en) *	2012-10-01	2018-03-20	Adaptive Biotechnologies Corporation	Evaluation of immunocompetence by the diversity of adaptive immunity receptors and clonal characterization
CA2896797A1 (en)	2013-01-11	2014-07-17	Dingfu Biotarget Co., Ltd	Agents for treating tumours, use and method thereof

2015
- 2015-06-16 US US14/740,876 patent/US10092645B2/en active Active
- 2015-06-17 WO PCT/EP2015/063552 patent/WO2015193352A1/en active Application Filing
- 2015-06-17 EP EP15733375.8A patent/EP3157629B1/en active Active
- 2015-06-17 KR KR1020227018740A patent/KR102592781B1/en active IP Right Grant
- 2015-06-17 EP EP22191482.3A patent/EP4144412A1/en active Pending
- 2015-06-17 HU HUE15733375A patent/HUE060689T2/en unknown
- 2015-06-17 JP JP2016573493A patent/JP6877147B2/en active Active
- 2015-06-17 DK DK15733375.8T patent/DK3157629T3/en active
- 2015-06-17 SG SG11201610600SA patent/SG11201610600SA/en unknown
- 2015-06-17 MX MX2016015346A patent/MX2016015346A/en unknown
- 2015-06-17 RU RU2017101312A patent/RU2711408C2/en active
- 2015-06-17 AU AU2015276173A patent/AU2015276173B2/en active Active
- 2015-06-17 TW TW110147753A patent/TWI781021B/en active
- 2015-06-17 BR BR112016028964A patent/BR112016028964A2/en not_active Application Discontinuation
- 2015-06-17 SG SG10202108654PA patent/SG10202108654PA/en unknown
- 2015-06-17 CN CN201580032538.3A patent/CN107073107A/en active Pending
- 2015-06-17 TW TW104119642A patent/TWI751101B/en active
- 2015-06-17 KR KR1020177000126A patent/KR20170015460A/en not_active Application Discontinuation
- 2015-06-17 CA CA2950046A patent/CA2950046C/en active Active
- 2015-06-17 PT PT157333758T patent/PT3157629T/en unknown
- 2015-06-17 PL PL15733375.8T patent/PL3157629T3/en unknown
- 2015-06-17 ES ES15733375T patent/ES2933603T3/en active Active
- 2015-06-17 KR KR1020237025257A patent/KR20230113847A/en not_active Application Discontinuation
2016
- 2016-11-22 IL IL249133A patent/IL249133B/en unknown
- 2016-11-23 MX MX2021004828A patent/MX2021004828A/en unknown
- 2016-11-23 MX MX2021004821A patent/MX2021004821A/en unknown
2018
- 2018-09-05 US US16/121,867 patent/US20190192655A1/en not_active Abandoned
2020
- 2020-03-26 JP JP2020056306A patent/JP2020121978A/en active Pending
- 2020-07-29 AU AU2020210207A patent/AU2020210207B2/en active Active
2021
- 2021-10-20 JP JP2021171547A patent/JP7258981B2/en active Active
2023
- 2023-04-05 JP JP2023061117A patent/JP2023093538A/en active Pending
- 2023-05-01 AU AU2023202654A patent/AU2023202654A1/en active Pending

Also Published As

Publication number	Publication date
EP4144412A1 (en)	2023-03-08
PT3157629T (en)	2022-12-20
RU2711408C2 (en)	2020-01-17
KR20230113847A (en)	2023-08-01
AU2020210207A1 (en)	2020-08-20
ES2933603T3 (en)	2023-02-10
IL249133B (en)	2022-04-01
EP3157629B1 (en)	2022-10-05
JP2022031638A (en)	2022-02-22
RU2017101312A (en)	2018-07-20
JP7258981B2 (en)	2023-04-17
HUE060689T2 (en)	2023-04-28
AU2020210207B2 (en)	2023-02-02
US10092645B2 (en)	2018-10-09
TW201617093A (en)	2016-05-16
IL249133A0 (en)	2017-01-31
EP3157629A1 (en)	2017-04-26
US20160051672A1 (en)	2016-02-25
CA2950046C (en)	2023-02-14
BR112016028964A2 (en)	2017-10-17
CN107073107A (en)	2017-08-18
AU2015276173B2 (en)	2020-08-20
JP2023093538A (en)	2023-07-04
WO2015193352A1 (en)	2015-12-23
JP2020121978A (en)	2020-08-13
TWI781021B (en)	2022-10-11
JP6877147B2 (en)	2021-05-26
SG10202108654PA (en)	2021-09-29
CA2950046A1 (en)	2015-12-23
US20190192655A1 (en)	2019-06-27
MX2016015346A (en)	2017-08-10
KR102592781B1 (en)	2023-10-20
AU2015276173A1 (en)	2016-12-22
JP2017525661A (en)	2017-09-07
DK3157629T3 (en)	2022-12-19
MX2021004828A (en)	2021-09-21
RU2017101312A3 (en)	2019-01-29
TW202228777A (en)	2022-08-01
TWI751101B (en)	2022-01-01
MX2021004821A (en)	2021-08-19
PL3157629T3 (en)	2023-01-30
KR20220082097A (en)	2022-06-16
KR20170015460A (en)	2017-02-08
AU2023202654A1 (en)	2023-05-18

Publication	Publication Date	Title
IL249133B (en)	2022-04-01	Methods of cancer treatment with antagonists against pd-1 and pd-l1 in combination with radiation therapy
HK1249524A1 (en)	2018-11-02	Immune-checkpoint inhibitors for use in the treatment of blood-borne cancers
HK1247848A1 (en)	2018-10-05	Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer
IL249658A0 (en)	2017-02-28	Methods of treating cancer using tigit inhibitors and anti-cancer agents
ZA201607415B (en)	2019-06-26	Antibody-drug-conjugate and its use for the treatment of cancer
IL249189A0 (en)	2017-01-31	Combination therapy of antibodies activating human cd40 and antibodies against human pd-l1
HRP20190888T8 (en)	2019-10-04	Igf-1r antibody-drug-conjugate and its use for the treatment of cancer
IL276733A (en)	2020-09-30	Use of eribulin in the treatment of cancer
GB201514021D0 (en)	2015-09-23	Novel Pyridines and their use in the treatment of cancer
IL259358A (en)	2018-07-31	Bis-pyridazine compounds and their use in treating cancer
EP3151821A4 (en)	2017-12-13	Marmelin analogs and methods of use in cancer treatment
HUE055747T2 (en)	2021-12-28	Combination of egfr inhibitor and mek inhibitor for use in the treatment of nras mutated cancer
GB201416605D0 (en)	2014-11-05	Combination therapy to reduce the risk of and to treat cancer
GB201411111D0 (en)	2014-08-06	bis-Pyridazine compounds and their use in treating cancer
GB201403086D0 (en)	2014-04-09	Selection of virus and agent useful in the treatment of cancer
GB201418640D0 (en)	2014-12-03	Agents and methods for treatment of cancer
GB201510764D0 (en)	2015-08-05	bis-Pyridazine compounds and their use in treating cancer
DK3092039T3 (en)	2022-10-24	Skin cancer treatment with radiation therapy